7yo golden retriever with a splenic mass on ultrasound

🧫

Colleague, this is a classic and concerning presentation. In a 7-year-old Golden, a splenic mass is hemangiosarcoma (HSA) until proven otherwise. The "rule of two-thirds" is a useful guide here: about two-thirds of splenic masses are malignant, and of those, two-thirds are HSA. My immediate priority is to turn panic into a clear, staged plan.

1. Pre-Operative Staging (Essential before surgery):
Before heading to the OR, we need to know what we're dealing with.
* 3-view thoracic radiographs: This is non-negotiable. If we have gross pulmonary metastasis, splenectomy shifts from a therapeutic to a palliative procedure (to prevent rupture), and the long-term prognosis is grave. The owner must understand this before committing to a major surgery.
* Full CBC, Chemistry, and Coagulation Panel: Anemia is common. Thrombocytopenia and evidence of DIC can be present and will significantly impact surgical risk.
* Abdominal Ultrasound Review: Confirm the mass is splenic, check for evidence of metastasis to the liver or mesentery, and carefully evaluate the right atrium for a concurrent cardiac mass, which occurs in up to 25% of cases.

2. Surgical Plan & Diagnosis:
Splenectomy is the next step, assuming no widespread metastasis. This is both therapeutic (removes the risk of rupture) and diagnostic.
* Crucially, submit the entire spleen for histopathology. Gross appearance is notoriously unreliable for differentiating a malignant tumor from a benign hematoma or nodular hyperplasia.

3. Adjuvant Therapy & Prognosis (The Post-Op Conversation):
This is where histopathology dictates our path.
* If benign (hematoma, nodular hyperplasia): The splenectomy is curative. Fantastic news.
* If Hemangiosarcoma: This is a difficult conversation, and we must be direct about prognosis.
* Splenectomy alone: Median survival time (MST) is unfortunately only 1-3 months.
* Splenectomy + adjuvant chemotherapy: The standard of care is single-agent doxorubicin. This can extend the MST to approximately 6 months. The goal is to provide good quality months, not just more months. Most dogs tolerate doxorubicin well.

The recommended protocol is doxorubicin 30 mg/m² IV every 3 weeks for 5-6 cycles. I always recommend a pre-chemo echocardiogram, especially in a predisposed breed.

Let's get the staging done first. That data will guide our conversation with the owner and help them make the most informed decision possible.

Dr. Rachel Torres 🧫

This is a classic and always concerning presentation, especially in this breed. My approach is systematic to ensure we have a complete picture before heading to the operating room.

First, comprehensive staging is non-negotiable. While the ultrasound identified the primary mass, we need to rule out gross metastatic disease which would significantly alter the prognosis and the owner's decisions.

Pre-operative Staging Plan:
* Thoracic Radiographs (3-view): Essential for screening for pulmonary metastasis.
* Abdominal Ultrasound Review: I'd want to personally review the images, looking for evidence of hemoabdomen (even scant), liver nodules, or other concurrent intra-abdominal masses. Dr. Lin's full report will be critical here.
* Echocardiogram: Strongly recommended. The right atrium is a common site for primary or metastatic hemangiosarcoma. Anesthesia for a splenectomy in a patient with a right atrial mass carries profoundly different risks.
* Lab Work: CBC (checking for anemia, schistocytes, thrombocytopenia), chemistry panel, and a coagulation profile (PT/PTT). Disseminated intravascular coagulation (DIC) is a known risk.

Assuming staging is clear, the surgical plan is a ventral midline celiotomy and total splenectomy. I perform a full abdominal exploratory, paying close attention to the liver surfaces and serosa of all organs. Any suspicious liver lesions should be biopsied (I prefer a guillotine or punch biopsy). The entire spleen is submitted for histopathology—this is the most critical step for prognosis.

The conversation with the owner must be frank. We use the "two-thirds/two-thirds" rule: roughly 2/3 of splenic masses are malignant, and of those, 2/3 are hemangiosarcoma. Surgery is both diagnostic and therapeutic, as it removes the risk of imminent, life-threatening hemorrhage. However, if this is hemangiosarcoma, surgery alone offers a median survival time of only 1-3 months. Dr. Torres's input on adjuvant chemotherapy will be essential for discussing long-term options post-histopathology.

Colleague, this is a critical finding, and a systematic approach is essential.

The most important principle here is that ultrasonography cannot reliably differentiate benign from malignant splenic masses. While hemangiosarcoma is a primary concern in this signalment, differentials must include hematoma, nodular hyperplasia, lymphoma, and other metastatic neoplasms. The "two-thirds/one-third" rule is a useful clinical guide: roughly two-thirds of canine splenic masses are malignant, and of those, two-thirds are hemangiosarcoma. However, this is a probability, not a diagnosis.

From an imaging perspective, our immediate goal is staging to guide treatment decisions.

Complete Abdominal Ultrasound: If not already performed, a full, systematic abdominal ultrasound is necessary. I'm looking for evidence of metastatic disease, specifically hepatic nodules, mesenteric or other lymphadenopathy, and evidence of peritoneal effusion (hemoabdomen). Characterize the splenic mass itself: is it cavitated? Is there active hemorrhage? Note the echotexture of the liver parenchyma.

Thoracic Radiographs: A three-view metastatic survey (right lateral, left lateral, and VD/DV) is the minimum standard of care. This is crucial for detecting pulmonary nodules. CT is significantly more sensitive for detecting small metastases (<7-9 mm) and should be considered if available and if it will alter the therapeutic plan.

My role is to provide a complete imaging stage. This will allow Dr. Okafor to assess surgical risk and Dr. Torres to discuss prognosis and potential adjuvant therapies. We describe the extent of the disease; pathology will provide the definitive diagnosis.